¼¼°èÀÇ ±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS) Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ¾à¹° À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº° ºÐ¼®(2023-2030³â)
Global Acute Respiratory Distress Syndrome Treatment Market Size study & Forecast, by Drug Class, By Route of Administration, By Distribution Channel and Regional Analysis, 2023-2030
»óǰÄÚµå : 1303557
¸®¼­Ä¡»ç : Bizwit Research & Consulting LLP
¹ßÇàÀÏ : 2023³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,946,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,771,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS)Àº Æó·Å, ÆÐÇ÷Áõ, ¿Ü»ó, ÈíÀÔ ¼Õ»ó µî ´Ù¾çÇÑ ±âÀú ¿øÀο¡ ¹ÝÀÀÇÏ¿© ¹ß»ýÇÒ ¼ö ÀÖ´Â ÁúȯÀÔ´Ï´Ù.

ARDS´Â ÆóÀÇ ¿°Áõ°ú ü¾× ÃàÀûÀ» Ư¡À¸·Î ÇÏ¸ç ½ÉÇÑ È£Èí°ï¶õ°ú È£Èí ºÎÀüÀ» À¯¹ßÇÕ´Ï´Ù. ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS) Ä¡·á ½ÃÀåÀº Á¶»ê Áõ°¡¿Í È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ È®´ëµÇ°í ÀÖÀ¸¸ç, ARDS Ä¡·á¿¡´Â ÀϹÝÀûÀ¸·Î È£ÈíÀ» µ½±â À§ÇÑ ±â°èÀû ÀΰøÈ£Èí, º¸Á¶ »ê¼Ò, Áõ»ó °ü¸® ¹× ÇÕº´Áõ ¿¹¹æÀ» À§ÇÑ ¾à¹° Ä¡·á¿Í °°Àº º¸Á¶ ¿ä¹ýÀÌ Æ÷ÇԵ˴ϴÙ. Àº Áö³­ ¼ö½Ê³âµ¿¾È Á¡Â÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, ¸Å³â ¾à 1,500¸¸ ¸íÀÇ ¾Æ±â°¡ Á¶»êÀ¸·Î ž´Ï´Ù. ¶ÇÇÑ, Á¶»êÀÇ ºñÀ²Àº ±¹°¡¿¡ µû¶ó 5%¿¡¼­ 18%±îÁö ´Ù¾çÇÕ´Ï´Ù. ¶ÇÇÑ Àú¼Òµæ ±¹°¡¿¡¼­ ž Ãʹ̼÷¾ÆÀÇ 90% ÀÌ»óÀÌ »ýÈÄ ¸çÄ¥ À̳»¿¡ »ç¸ÁÇÏ´Â ¹Ý¸é, °í¼Òµæ ±¹°¡¿¡¼­ »ç¸ÁÇÏ´Â Ãʹ̼÷¾Æ´Â 10% ¹Ì¸¸ÀÔ´Ï´Ù. ¿ìÁÖ¸¦ ÃßÁøÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿ä¼Ò´Â È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡ÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, 2019³â õ½ÄÀº ¾à 2¾ï 6,200¸¸ ¸íÀÌ ¾Î¾Ò°í, 4¾ï 5,500¸¸ ¸íÀÌ »ç¸ÁÇß½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼ºÆó¼â¼ºÆóÁúȯÀº ¼¼°è 3À§ÀÇ »ç¸Á¿øÀÎÀ̸ç, 2019³â 70¼¼ ¹Ì¸¸ COPD·Î ÀÎÇÑ »ç¸ÁÀÚÀÇ 90% °¡±îÀ̰¡ ÁßÀú¼Òµæ ±¹°¡¿¡¼­ ¹ß»ýÇØ 323¸¸ ¸íÀÌ »ç¸ÁÇß½À´Ï´Ù. ¶ÇÇÑ, Áø´Ü ¼ö¿ä Áõ°¡¿Í ÀÇ·á °Ë»ç ÀåºñÀÇ ±â¼ú ¹ßÀüÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå Àü¸ÁÀ» Á¦°øÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ±×·¯³ª ±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS) Ä¡·áÀÇ ³ôÀº ºñ¿ëÀº 2023-2030³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ARDS) Ä¡·áÁ¦ ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ±â¼ú ¹ßÀü°ú Ä¡·á °úÁ¤À» °³¼±Çϱâ À§ÇÑ ¼ö¸¹Àº ÷´Ü ¾à¸®ÇÐ ºÐÀÚÀÇ °¡¿ë¼ºÀ¸·Î ÀÎÇØ 2022³â ½ÃÀåÀ» Àå¾ÇÇßÀ¸¸ç, Statista¿¡ µû¸£¸é ¹Ì±¹ÀÇ ¸¸¼ºÆó¼â¼ºÆóÁúȯ À¯º´·üÀº 2050³â±îÁö ¼ºÀÎÀÇ ¾à 11.6%±îÁö Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½ÃÀå °ø°£¿¡¼­ »ý¸í °øÇÐ ¿¬±¸ ¹× ¼¾ÅÍ È°µ¿ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³âµ¿¾È ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³âµ¿¾È ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû/¾çÀû Ãø¸éÀ» Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸ¿¡ ´ëÇØ¼­µµ ´Ù·ç¾ú½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS) Ä¡·á ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

Á¦3Àå ¼¼°èÀÇ ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS) Ä¡·á ½ÃÀå ¿ªÇÐ

Á¦4Àå ¼¼°èÀÇ ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS) Ä¡·á ½ÃÀå »ê¾÷ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS) Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

Á¦6Àå ¼¼°èÀÇ ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS) Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°

Á¦7Àå ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS) Ä¡·áÁ¦ ¼¼°è ½ÃÀå : À¯Åë ä³Îº°

Á¦8Àå ¼¼°èÀÇ ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS) Ä¡·á ½ÃÀå : Áö¿ªº° ºÐ¼®

Á¦9Àå °æÀï Á¤º¸

Á¦10Àå Á¶»ç °úÁ¤

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Acute Respiratory Distress Syndrome Treatment Market is valued at approximately USD xxx billion in 2022 and is anticipated to grow with a healthy growth rate of more than xx% over the forecast period 2023-2030. Acute Respiratory Distress Syndrome is a medical condition that can occur in response to various underlying causes, such as pneumonia, sepsis, trauma, or inhalation injury. ARDS is characterized by inflammation and fluid buildup in the lungs, which can lead to severe shortness of breath and respiratory failure. The Acute Respiratory Distress Syndrome Treatment market is expanding because of factors such as increasing cases of Preterm birth and growing prevalence of respiratory diseases. Treatment of ARDS typically involves supportive care, such as mechanical ventilation to help with breathing, supplemental oxygen, and medications to manage symptoms and prevent complications. Its prevalence has progressively increased during the last few decades.

According to the World Health Organization, every year, an estimated 15 million babies are born preterm. Furthermore, across countries, the rate of preterm birth ranges from 5% to 18% of babies born. Moreover, more than 90% of extremely preterm babies born in low-income countries die within the first few days of life, yet less than 10% of extremely preterm babies die in high-income settings. Another important component driving space is increased prevalence of respiratory diseases. According to World Health Organization, Asthma affected an estimated 262 million people in 2019 and caused 455 000 deaths. In addition, Chronic obstructive pulmonary disease is the third leading cause of death worldwide, causing 3.23 million deaths Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries in 2019. Also, increasing demand for diagnosis and rising technological advancement in medical testing devices would create a lucrative growth prospectus for the market over the forecast period. However, the high cost of Acute Respiratory Distress Syndrome Treatment stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Acute Respiratory Distress Syndrome Treatment Market study include: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to technological advancements and the availability of numerous cutting-edge pharmacological molecules to improve the therapeutic process. According to Statista, the prevalence of chronic obstructive pulmonary disease in the United States is expected to increase to around 11.6% among adults by the year 2050. Asia Pacific is expected to grow significantly during the forecast period, owing to an increase in biotechnology research and center activity in the market space.

Major market players included in this report are:

Recent Developments in the Market:

Global Acute Respiratory Distress Syndrome Treatment Market Report Scope:

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Class

By Route of Administration

By Distribution Channel

By Region:

Table of Contents

Chapter 1. Executive Summary

Chapter 2. Global Acute Respiratory Distress Syndrome Treatment Market Definition and Scope

Chapter 3. Global Acute Respiratory Distress Syndrome Treatment Market Dynamics

Chapter 4. Global Acute Respiratory Distress Syndrome Treatment Market Industry Analysis

Chapter 5. Global Acute Respiratory Distress Syndrome Treatment Market, by Drug Class

Chapter 6. Global Acute Respiratory Distress Syndrome Treatment Market, by Route of Administration

Chapter 7. Global Acute Respiratory Distress Syndrome Treatment Market, by Distribution Channel

Chapter 8. Global Acute Respiratory Distress Syndrome Treatment Market, Regional Analysis

Chapter 9. Competitive Intelligence

Chapter 10. Research Process

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â